All In Biotech

Drug Trial Radar · NCT01851330

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection

Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 647 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

647

Actual

Start

May 2013

Primary completion

Dec 2013

Study completion Mar 2014

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
May 10, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive participants with chronic genotype 1 HCV infection.

Conditions

  • Chronic Hepatitis C Virus

Interventions

  • LDV/SOFDrug

    LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily

  • RBVDrug

    Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Time frame: Posttreatment Week 12
  2. Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study DrugTime frame: Up to 12 weeks

Locations

52 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Palo Alto, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Englewood, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Wellington, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Bowling Green, Kentucky

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Lutherville, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Novi, Michigan

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Albuquerque, New Jersey

  • Site not named

    Berlin, New Jersey

  • Site not named

    Hillsborough, New Jersey

  • Site not named

    Santa Fe, New Mexico

  • Site not named

    Binghamton, New York

  • Site not named

    Manhasset, New York

  • Site not named

    New York, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Fayetteville, North Carolina

  • Site not named

    Statesville, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Philadelphia, Pennsylvania

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.